The monotherapy of olutasidenib, an effective and specific inhibitor of IDH1 mutation, has shown impressive and sustained remission rates, as well as significant outcomes like transfusion independence, among patients with relapsed or refractory (R/R) IDH1mut AML (Venugopal and Watts, 2023). This evidence concerns the gene IDH1 and acute myeloid leukemia.